Merck & Co’s CEO Kenneth Frazier has said the pharma industry must take on the challenge of its poor public perception. In an interview with Yahoo Finance, Frazier defended the industry’s ...

PETRA Diamonds today announced the resignation of its CEO Richard Duffy ending nearly six – largely difficult – years at the company blighted by poor trading conditions which has forced the UK-listed ...

Israeli drugmaker Teva has appointed former Sandoz and Biogen executive Richard Francis to succeed current CEO Kare Schultz, who is scheduled to retire at the end of this year. Francis ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...

Spanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to lead Merck KGaA’s healthcare unit earlier this month ...

Richard Leadbetter is the founder of Digital Foundry and Technology Editor for Eurogamer.net. Digital Foundry began life in 2004 as a video production facility and videogames consultancy business ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...